CPRX Catalyst Pharmaceuticals $40M Repurchase P/E Ratio 6.5 WOW

Catalyst Pharmaceuticals is a biopharmaceutical company that specializes in therapies for rare neurological and neuromuscular diseases. It announced its fourth-quarter and 2020 financial results on March 15, 2021, reporting a 16% increase in revenue for fiscal 2020 and a 30% increase in operating income. (investopedia.com)
The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share.
The company remains focused on acquiring or in-licensing innovative, technology platforms and early stage programs in therapeutic areas different from neuromuscular diseases. (smarteranalyst.com)

CPRX it`s an easy 50% in my opinion.
$40 Million Share Repurchase.
Market Cap 453.715M.
PE Ratio (TTM) 6.15.
75mil revenue, 119mil earnings in 2020
haven`t seen such a great balance sheet on a penny stock.
now trading at 4,94usd.
3/18/2021 Roth Capital Boost Price Target Buy $6.50 ➝ $7.00
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on the stock with a price target of $9

If you are also interested to test some amazing BUY and SELL INDICATORS that i use, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.